Difference between revisions of "Prothrombin complex concentrates"

(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Pregnancy Rating: *Lac...")
 
(created PCC page)
Line 1: Line 1:
 
==General==
 
==General==
*Type:  
+
*Type: Hemostatics, blood components
*Dosage Forms:
+
*Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
*Common Trade Names:  
+
*Common Trade Names: Kcentra
  
 
==Adult Dosing==
 
==Adult Dosing==
 
+
*Based on pretreatment INR, units based on factor 9 content
 +
**INR2-<4: 25units/kg, not to exceed 2500 units
 +
**INR4-<6: 35units/kg, not to exceed 3500 units
 +
**INR>6: 50units/kg, not to exceed 5000 units
 
==Pediatric Dosing==
 
==Pediatric Dosing==
 +
Safety and efficacy not established
  
 
==Special Populations==
 
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
+
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*Lactation:
+
*Lactation: Unknown, breast feeding not advised
 
*Renal Dosing
 
*Renal Dosing
**Adult
+
**Adult-N/A
**Pediatric
+
**Pediatric-N/A
 
*Hepatic Dosing
 
*Hepatic Dosing
**Adult
+
**Adult-N/A
**Pediatric
+
**Pediatric-N/A
  
 
==Contraindications==
 
==Contraindications==
 
*Allergy to class/drug
 
*Allergy to class/drug
 +
*DIC
 +
*known HIT (Heparin induced thrombocytopenia)
  
==Adverse Reactions==
 
 
===Serious===
 
===Serious===
 
+
*thromboembolism
 +
*blood product (hepatitis, HIV)
 
===Common===
 
===Common===
 +
*thromboembolic events (8.7%)
 +
*headache (7.8%)
 +
*hypotension (4.9%)
 +
*nausea/vomiting
 +
*arthralgia
 +
*ICH (2.9%)
 +
*mental status change (2.9%)
 +
*hypertension (2.9%)
  
 
==Pharmacology==
 
==Pharmacology==
Line 35: Line 49:
  
 
==Sources==
 
==Sources==
 
+
Medscape
 
<references/>
 
<references/>
 
[[Category:Drugs]]
 
[[Category:Drugs]]

Revision as of 13:44, 28 May 2015

General

  • Type: Hemostatics, blood components
  • Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
  • Common Trade Names: Kcentra

Adult Dosing

  • Based on pretreatment INR, units based on factor 9 content
    • INR2-<4: 25units/kg, not to exceed 2500 units
    • INR4-<6: 35units/kg, not to exceed 3500 units
    • INR>6: 50units/kg, not to exceed 5000 units

Pediatric Dosing

Safety and efficacy not established

Special Populations

  • Pregnancy Rating: C
  • Lactation: Unknown, breast feeding not advised
  • Renal Dosing
    • Adult-N/A
    • Pediatric-N/A
  • Hepatic Dosing
    • Adult-N/A
    • Pediatric-N/A

Contraindications

  • Allergy to class/drug
  • DIC
  • known HIT (Heparin induced thrombocytopenia)

Serious

  • thromboembolism
  • blood product (hepatitis, HIV)

Common

  • thromboembolic events (8.7%)
  • headache (7.8%)
  • hypotension (4.9%)
  • nausea/vomiting
  • arthralgia
  • ICH (2.9%)
  • mental status change (2.9%)
  • hypertension (2.9%)

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

See Also

Sources

Medscape